Strongbridge Biopharma PLC (NASDAQ:SBBP)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Wednesday.
A number of other brokerages also recently issued reports on SBBP. Zacks Investment Research downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. assumed coverage on Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $11.81.
Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) opened at $5.75 on Wednesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 4.46 and a current ratio of 4.63. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85.
Several large investors have recently modified their holdings of SBBP. Lyon Street Capital LLC acquired a new stake in shares of Strongbridge Biopharma PLC during the 3rd quarter worth about $2,862,000. Northern Trust Corp acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $1,462,000. Caxton Corp grew its position in Strongbridge Biopharma PLC by 2.2% in the 3rd quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock valued at $38,053,000 after acquiring an additional 120,000 shares in the last quarter. Nexthera Capital LP acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $477,000. Finally, Vanguard Group Inc. acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $474,000. 56.53% of the stock is owned by hedge funds and other institutional investors.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.